Preferred Label : CLEC12A-targeting CCR/Anti-ADGRE2 CAR T Cells ADCLEC.syn1;
NCIt synonyms : ADCLEC.syn1; CLL-1-targeting CCR/Anti-ADGRE2 CAR-T Cells ADCLEC.syn1; CLL1-targeting CCR/Anti-ADGRE2 CAR-expressing T-cells ADCLEC.syn1;
NCIt definition : A preparation of T-lymphocytes that have been genetically modified to express a chimeric
antigen receptor (CAR) specific for the human myeloid-restricted adhesion G protein-coupled
receptor E2 (ADGRE2; EGF-like module receptor 2; EMR2; CD312), and a chimeric costimulatory
receptor (CCR) targeting C-type lectin domain family 12 member A (CLEC12A, C-type-lectin-like
molecule-1; CLL-1; CLL1), with potential immunomodulating and antineoplastic activities.
Upon administration, CLEC12A-targeting CCR/anti-ADGRE2 CAR T cells ADCLEC.syn1 target
and bind to ADGRE2- and CLEC12A-expressing tumor cells. This induces selective toxicity
in tumor cells that express a high level of ADGRE2, and tumor cells that express both
ADGRE2 and CLEC12A. ADGRE2 is expressed mainly on myeloid cells and is overexpressed
on leukemic stem cells (LSCs) in acute myeloid leukemia (AML). CLEC12A, a member of
the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily, is overexpressed
on LSCs and plays an important role in disease progression and relapse for myeloid
malignancies. ADGRE2 and CLEC12A are highly co-expressed in AML and not in normal
tissues. Targeting both ADGRE2 and CLEC12A may improve efficacy and reduce adverse
effects.;
NCI Metathesaurus CUI : CL1907090;
Origin ID : C200268;
concept_is_in_subset
- has_target
